Sequel and Senseonics are teaming up on a development agreement aimed at transforming diabetes care.
The collaboration will involve the integration of Sequel’s twiist Automated Insulin Delivery (AID) system with Senseonics’ Eversense 365, the first one-year continuous glucose monitoring (CGM) system.
Go deeper with GlobalData
With Sequel’s twiist set to become the first AID system compatible with Eversense 365, the companies said the move will provide type 1 diabetes patients with increased flexibility and personalisation in managing their condition.
Eversense 365 went on sale in the US in October 2024 following approval from the US Food and Drug Administration (FDA) in September for continually measuring glucose levels for up to one year in diabetes patients aged 18 and above. The system is indicated for use to replace fingerstick blood glucose measurements for diabetes treatment decisions.
According to Senseonics, which filed for European CE mark registration for the implantable device in February, Eversense 365 ideates on the traditional short-term CGMs, offering advantages to type 1 diabetes patients with its one-year sensor lifespan, minimal data interruptions, and fewer wasted sensors.
Senseonics president and CEO Tim Goodnow said the integration with Sequel, which is expected to be available by Q3 2025, would result in a “significant step forward” in diabetes care.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“People with diabetes who choose the convenience and ease of our one-year CGM sensor have been waiting for a compatible AID system to enhance their diabetes management,” Goodnow explained.
“The synergy of Eversense and twiist will provide people with diabetes our most recent innovations in advanced pump, algorithm, and sensor technologies to simplify diabetes management, providing users with an AID solution that unlocks the full experience of our year-long CGM technology.”
According to GlobalData analysis, the overall global diabetes care market is estimated to reach a valuation of $44bn by 2033, up from $25bn in 2023.
Elsewhere in the diabetes space, Abbott recently reported a 27% uptick in diabetes device sales in Q1 2025, bringing diabetes sales in the US alone to $748m compared to the $1.08bn generated internationally for its Diabetes Care unit. Last year, the device giant opened a new manufacturing facility in Ireland focused on the global manufacturing of sensors for its CGM diabetes devices.
